Antipsychotics are the cornerstone of treatment for psychotic and some nonpsychotic
disorders. However, despite pharmacologic advances, considerable areas of need remain …

Schizophrenia is a chronic and debilitating condition with a global prevalence of
approximately 1% varying by location and diagnostic criterion. 1, 2 The average age of …

Schizophrenia was first labeled medically at the beginning of the twentieth century, although
depictions of the illness can be found throughout recorded history. During the nineteenth …

The past 5 years have witnessed an intense period of change in the pharmacotherapy of
schizophrenia. Several new antipsychotic agents have become available for clinical use …

The management of schizophrenia continues to represent an enormous challenge, despite
improvements in both drug therapy and family and community interventions. Treatment …

Historically, schizophrenia has been associated with early-onset, persistent symptoms, and
progressive decline accompanied by poor functional recovery. The advent of effective drugs …

Patients with schizophrenia have a chronic illness necessitating a biopsychosocial model of
care that addresses the multiple dimensions of the disease, including coordinated primary …

Introduction Schizophrenia is often associated with chronic disability and poor outcome. In
addition to positive symptoms, such as hallucinations and delusions, and negative …

Objectives: This article are to describe current trends in the treatment of schizophrenia and
the most interesting new approaches to optimizing outcome and fostering the development …